The efficacy of triple therapy in therapy-naïve and relapser patients with HCV-1 chronic hepatitis was greater than that of dual therapy regardless of the IL-28B genotype, the severity of liver fibrosis, HCV sub-genotype, and HCV load at the baseline, thus indicating that these factors do not affect the different efficacy between dual and triple therapy in these patients. This evidence concerns the gene IFNL3 and Hepatic fibrosis.